Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Aroda, Vanita R; Bain, Steve; Cariou, Bertrand; Piletič, Milivoj; Rose, Ludger; Axelsen, Mads; Rowe, Everton; DeVries, J Hans

doi:10.1016/S2213-8587(17)30085-2

Journal article 1649 views 2394 downloads

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, paralle...

Vanita R Aroda, Steve Bain

, Bertrand Cariou, Milivoj Piletič, Ludger Rose, Mads Axelsen, Everton Rowe, J Hans DeVries

The Lancet Diabetes and Endocrinology, Volume: 5, Issue: 5, Pages: 355 - 366

Swansea University Author: Steve Bain

PDF | Accepted Manuscript
Download (926.47KB)

Check full text

DOI (Published version): 10.1016/S2213-8587(17)30085-2

Published in:	The Lancet Diabetes and Endocrinology
ISSN:	22138587
Published:	2017
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa31639

first_indexed	2017-01-18T14:53:38Z
last_indexed	2020-07-14T12:55:22Z
id	cronfa31639
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2020-07-14T12:32:18.7868776</datestamp><bib-version>v2</bib-version><id>31639</id><entry>2017-01-18</entry><title>Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-01-18</date><deptcode>MEDS</deptcode><abstract/><type>Journal Article</type><journal>The Lancet Diabetes and Endocrinology</journal><volume>5</volume><journalNumber>5</journalNumber><paginationStart>355</paginationStart><paginationEnd>366</paginationEnd><publisher/><issnPrint>22138587</issnPrint><keywords/><publishedDay>31</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-05-31</publishedDate><doi>10.1016/S2213-8587(17)30085-2</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-07-14T12:32:18.7868776</lastEdited><Created>2017-01-18T08:25:28.4206481</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Vanita R</firstname><surname>Aroda</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author><author><firstname>Bertrand</firstname><surname>Cariou</surname><order>3</order></author><author><firstname>Milivoj</firstname><surname>Piletič</surname><order>4</order></author><author><firstname>Ludger</firstname><surname>Rose</surname><order>5</order></author><author><firstname>Mads</firstname><surname>Axelsen</surname><order>6</order></author><author><firstname>Everton</firstname><surname>Rowe</surname><order>7</order></author><author><firstname>J Hans</firstname><surname>DeVries</surname><order>8</order></author></authors><documents><document><filename>0031639-18012017083234.pdf</filename><originalFilename>Aroda2017.pdf</originalFilename><uploaded>2017-01-18T08:32:34.3230000</uploaded><type>Output</type><contentLength>999657</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><embargoDate>2017-07-23T00:00:00.0000000</embargoDate><copyrightCorrect>true</copyrightCorrect></document></documents><OutputDurs/></rfc1807>
spelling	2020-07-14T12:32:18.7868776 v2 31639 2017-01-18 Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2017-01-18 MEDS Journal Article The Lancet Diabetes and Endocrinology 5 5 355 366 22138587 31 5 2017 2017-05-31 10.1016/S2213-8587(17)30085-2 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2020-07-14T12:32:18.7868776 2017-01-18T08:25:28.4206481 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Vanita R Aroda 1 Steve Bain 0000-0001-8519-4964 2 Bertrand Cariou 3 Milivoj Piletič 4 Ludger Rose 5 Mads Axelsen 6 Everton Rowe 7 J Hans DeVries 8 0031639-18012017083234.pdf Aroda2017.pdf 2017-01-18T08:32:34.3230000 Output 999657 application/pdf Accepted Manuscript true 2017-07-23T00:00:00.0000000 true
title	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
spellingShingle	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial Steve Bain
title_short	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_full	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_fullStr	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_full_unstemmed	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
title_sort	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
author_id_str_mv	5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv	5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author	Steve Bain
author2	Vanita R Aroda Steve Bain Bertrand Cariou Milivoj Piletič Ludger Rose Mads Axelsen Everton Rowe J Hans DeVries
format	Journal article
container_title	The Lancet Diabetes and Endocrinology
container_volume	5
container_issue	5
container_start_page	355
publishDate	2017
institution	Swansea University
issn	22138587
doi_str_mv	10.1016/S2213-8587(17)30085-2
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	1
active_str	0
published_date	2017-05-31T01:11:30Z
_version_	1821275314375884800
score	11.047306

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, paralle...

Similar Items